• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Establishment Labs Holdings Inc. (Amendment)

    2/14/23 3:44:21 PM ET
    $ESTA
    Industrial Specialties
    Health Care
    Get the next $ESTA alert in real time by email
    SC 13G/A 1 esta.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (AMENDMENT NO. 3)* Establishment Labs Holdings Inc. (Name of Issuer) Common Stock (Title of Class of Securities) G31249108 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [ ] Rule 13d-1(b) [ X ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. G31249108 13G Page 2 of 7 Pages 1. NAMES OF REPORTING PERSONS OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Pura Vida Investments, LLC 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) [ ] (b) [ x ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 1,002,767* 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 1,002,767* 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,002,767* 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.12%** 12. TYPE OF REPORTING PERSON (see instructions) IA CUSIP No. G31249108 13G Page 3 of 7 Pages 1. NAMES OF REPORTING PERSONS OR I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Efrem Kamen 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) [ ] (b) [ x ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION USA NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 1,002,767* 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 1,002,767* 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,002,767* 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 4.12%** 12. TYPE OF REPORTING PERSON (see instructions) IN, HC CUSIP No. G31249108 13G Page 4 of 7 Pages Item 1. (a) Name of Issuer Establishment Labs Holdings Inc. (b) Address of Issuers Principal Executive Offices Building B15 and 25, Coyol Free Zone, Alajuela, Costa Rica Item 2. (a) Name of Person Filing Pura Vida Investments, LLC Efrem Kamen (collectively, the "Filers"). (b) The address of the principal place of the Filers is located at: Pura Vida Investments, LLC 512 West 22nd Street, 7th Floor, New York, NY 10022 (c) For citizenship of Filers, see Item 4 of the cover sheet for each Filer. (d) Title of Class of Securities Common Stock (e) CUSIP Number G31249108 Item 3. If this statement is filed pursuant to Rules 13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) [x] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1) (ii)(F); (g) [ ] A parent holding company or control person in accordance with Rule 13d-1(b)(1) (ii)(G); (h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] Group, in accordance with Rule 13d-1(b)(1)(ii)(J). CUSIP No. G31249108 13G Page 5 of 7 Pages Item 4. Ownership. (a) Amount beneficially owned: Pura Vida Investments LLC 1,002,767* shares Efrem Kamen 1,002,767* shares (b) Percent of class: Pura Vida Investments LLC 4.12%** Efrem Kamen 4.12%** (c) Number of shares as to which the person has: (i) Sole power to vote or to direct the vote 0 (ii) Shared power to vote or to direct the vote Pura Vida Investments LLC 1,002,767* shares Efrem Kamen 1,002,767* shares (iii) Sole power to dispose or to direct the disposition of 0 (iv) Shared power to dispose or to direct the disposition of Pura Vida Investments, LLC 1,002,767* shares Efrem Kamen 1,002,767* shares *Shares reported herein are owned by Pura Vida Master Fund, Ltd. (the "Pura Vida Master Fund") and certain separately managed accounts (the "Managed Accounts," collectively the "Client Accounts"). Pura Vida Investments, LLC ("PVI") serves as the investment manager or sub-adviser to the Client Accounts. Efrem Kamen serves as the Managing Member of PVI. Efrem Kamen serves as the managing member of PVI. By virtue of these relationships, the Reporting Persons may be deemed to have shared voting and dispositive power with respect to the Shares owned directly by the Pura Vida Master Fund and the Managed Accounts. This report shall not be deemed an admission that the Reporting Persons are beneficial owners of the Shares for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the Reporting Persons disclaims beneficial ownership of the Shares reported herein except to the extent of the Reporting Persons pecuniary interest therein. **The percentages herein are calculated based upon 24,342,327 shares of Common Stock of the Issuer outstanding per the Issuers Form 10-Q filed with the Securities and Exchange Commission on November 8, 2022. Item 5. Ownership of Five Percent or Less of a Class. N/A Item 6. Ownership of More than Five Percent on Behalf of Another Person. N/A Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company. N/A CUSIP No. G31249108 13G Page 6 of 7 Pages Item 8. Identification and Classification of Members of the Group. N/A Item 9. Notice of Dissolution of Group. N/A Item 10. Certification. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect. Exhibits. Exhibit A Joint Filing Agreement. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated: February 14, 2023 Pura Vida Investments, LLC By: /s/ Efrem Kamen, Managing Member CUSIP No. G31249108 13G Page 7 of 7 Pages EXHIBIT A AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned hereby consent and agree to file a joint statement on Schedule 13G under the Securities Exchange Act of 1934, as amended, with respect to the Pura Vida Investments, LLC. beneficially owned by them, together with any or all amendments thereto, when and if appropriate. The parties hereto further consent this Statement pursuant to Rule 13d-1(k)(1)(iii) as an exhibit to Schedule 13G, thereby incorporating the same into such Schedule 13G. Dated: February 14, 2023 Pura Vida Investments, LLC By: /s/ Efrem Kamen, Managing Member
    Get the next $ESTA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ESTA

    DatePrice TargetRatingAnalyst
    8/20/2025$60.00Buy
    Canaccord Genuity
    5/16/2025$62.00Buy
    BTIG Research
    5/14/2025$48.00Hold → Buy
    Needham
    4/14/2025Hold
    Needham
    5/22/2024$60.00Buy → Neutral
    Citigroup
    8/31/2023$75.00Overweight
    JP Morgan
    6/29/2023$79.00Buy
    Citigroup
    10/14/2022$90.00Overweight
    Stephens
    More analyst ratings

    $ESTA
    SEC Filings

    View All

    Establishment Labs Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)

    10/3/25 6:49:45 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Establishment Labs Holdings Inc.

    SCHEDULE 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

    8/13/25 11:39:05 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    SEC Form 10-Q filed by Establishment Labs Holdings Inc.

    10-Q - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Filer)

    8/7/25 5:24:07 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    $ESTA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lewin Nicholas Sheridan bought $98,410 worth of shares (2,600 units at $37.85) (SEC Form 4)

    4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

    8/14/25 10:58:27 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Director Lewin Nicholas Sheridan bought $78,880 worth of shares (2,300 units at $34.30) (SEC Form 4)

    4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

    8/13/25 11:02:28 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Amendment: Chief Executive Officer Caldini Filippo bought $100,320 worth of shares (2,850 units at $35.20), increasing direct ownership by 9% to 35,245 units (SEC Form 4)

    4/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

    8/11/25 4:02:37 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    $ESTA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ESTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ESTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Establishment Labs to Announce Third Quarter 2025 Financial Results on November 5

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended September 30, 2025, before the market opens on Wednesday, November 5, 2025, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or +1 (201) 689-8037 (International) and use conference ID number 13750830. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at ww

    10/22/25 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Establishment Labs Notes Publication of Mia Femtech 3-Year Prospective Study Results in Aesthetic Surgery Journal

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, noted the publication of "The 3-Year Results of a 100-Patient Prospective Study of Safety and Effectiveness of Mia Femtech" in the Aesthetic Surgery Journal. The study showed a very low rate of complications, with no reports of capsular contracture (Baker Grade III/IV), implant rupture (including a 33-patient MRI cohort), nipple or breast sensitivity loss, incision-related complications, infection, seroma, rippling, hematoma, or BIA-ALCL; the reoperation rate at 3 years was 1%. Patient and surgeon satis

    10/14/25 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Establishment Labs Publishes 15 Years of Motiva Data in 2025 Post-Market Surveillance Report

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced publication of its 2025 Post-Market Surveillance (PMS) Report. The report is being released ahead of the annual meeting of the American Society of Plastic Surgeons held October 9-12 in New Orleans. "Publishing our PMS report every year since the launch of Motiva in 2010 shows our dedication to accountability and transparency," said Peter Caldini, Establishment Labs Chief Executive Officer. "No other company in our industry publishes this level of information on an annual basis, and I would enc

    10/9/25 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Canaccord Genuity initiated coverage on Establishment Labs with a new price target

    Canaccord Genuity initiated coverage of Establishment Labs with a rating of Buy and set a new price target of $60.00

    8/20/25 8:52:36 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    BTIG Research initiated coverage on Establishment Labs with a new price target

    BTIG Research initiated coverage of Establishment Labs with a rating of Buy and set a new price target of $62.00

    5/16/25 8:05:11 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Establishment Labs upgraded by Needham with a new price target

    Needham upgraded Establishment Labs from Hold to Buy and set a new price target of $48.00

    5/14/25 8:49:26 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Director Schutter Edward J was granted 457 shares, increasing direct ownership by 0.33% to 138,015 units (SEC Form 4)

    4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

    10/1/25 5:39:22 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    Director Slotkin Bryan was granted 396 shares, increasing direct ownership by 1% to 29,748 units (SEC Form 4)

    4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

    10/1/25 5:39:04 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    Director Custin Ann was granted 503 shares, increasing direct ownership by 2% to 21,087 units (SEC Form 4)

    4 - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Issuer)

    10/1/25 5:38:46 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    $ESTA
    Leadership Updates

    Live Leadership Updates

    View All

    Establishment Labs Publishes 15 Years of Motiva Data in 2025 Post-Market Surveillance Report

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced publication of its 2025 Post-Market Surveillance (PMS) Report. The report is being released ahead of the annual meeting of the American Society of Plastic Surgeons held October 9-12 in New Orleans. "Publishing our PMS report every year since the launch of Motiva in 2010 shows our dedication to accountability and transparency," said Peter Caldini, Establishment Labs Chief Executive Officer. "No other company in our industry publishes this level of information on an annual basis, and I would enc

    10/9/25 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Establishment Labs Appoints Peter Caldini as Chief Executive Officer

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, announced today the appointment of Peter Caldini as Chief Executive Officer effective May 7, 2025. Mr. Caldini has served as Interim CEO since March 1, 2025, when Establishment Labs' Founder and previous CEO Juan José Chacón-Quirós retired from the role. "After an extensive search process, it was clear that with his deep operational, commercial, and financial skills, Peter is the ideal person to lead Establishment Labs," commented Nick Lewin, Chairman of the Board of Establishment Labs. "We have a vision

    5/7/25 4:00:00 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    Establishment Labs Announces CEO Transition

    Peter Caldini to become Interim CEO effective March 1, 2025 Establishment Labs also announces preliminary unaudited fourth quarter revenue in line with recent guidance Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness in breast aesthetics and reconstruction, announced today that after twenty years as Chief Executive Officer (CEO), Juan José Chacón-Quirós has decided to retire as CEO, effective March 1, 2025. Peter Caldini, currently President of Establishment Labs, will serve as Interim CEO after that date. Mr. Chacón-Quirós will continue with Establishment Labs as both a board member and an active

    1/13/25 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    $ESTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Establishment Labs Holdings Inc.

    SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

    11/12/24 12:54:20 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    SEC Form SC 13G filed by Establishment Labs Holdings Inc.

    SC 13G - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

    11/12/24 9:03:38 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    SEC Form SC 13G/A filed by Establishment Labs Holdings Inc. (Amendment)

    SC 13G/A - ESTABLISHMENT LABS HOLDINGS INC. (0001688757) (Subject)

    2/14/24 4:51:40 PM ET
    $ESTA
    Industrial Specialties
    Health Care

    $ESTA
    Financials

    Live finance-specific insights

    View All

    Establishment Labs to Announce Third Quarter 2025 Financial Results on November 5

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended September 30, 2025, before the market opens on Wednesday, November 5, 2025, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (877) 407-8037 (U.S. and Canada) or +1 (201) 689-8037 (International) and use conference ID number 13750830. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at ww

    10/22/25 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Establishment Labs Reports Second Quarter 2025 Financial Results

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, today announced financial results for the second quarter ended June 30, 2025. Second Quarter Highlights and Outlook (Unaudited) Second quarter worldwide revenue of $51.3 million, an increase of 16.3% from the year ago period. Revenue included $10.3 million of Motiva sales in the United States. 2025 revenue guidance increased to $208 million to $212 million from $205 million to $210 million, year over year growth of 25%–28%, with at least $40 million in US Motiva revenue. Second quarter gross ma

    8/7/25 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care

    Establishment Labs to Announce Second Quarter 2025 Financial Results on August 7

    Establishment Labs Holdings Inc. (NASDAQ:ESTA), a global medical technology company dedicated to improving women's health and wellness, principally in breast aesthetics and reconstruction, plans to announce its financial results for the quarter ended June 30, 2025, before the market opens on Thursday, August 7, 2025, and will host a conference call at 8:30 am ET that day to discuss those results. To participate in the conference call, dial (416) 764 8646 (U.S. and Canada) or +1 (888) 396 8049 (International) and use conference ID number 13750829. The call will also be available via live or archived webcast on the "Investor Relations" section of the Establishment Labs website at www.establ

    7/25/25 8:00:00 AM ET
    $ESTA
    Industrial Specialties
    Health Care